Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clade C gp140 HIV bivalent vaccine
- Development stage
- Discontinued
- Lead developer
- Janssen Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Clade C gp140 HIV bivalent vaccine (JNJ-65184340) is an investigational recombinant bivalent protein subunit vaccine developed by Janssen Vaccines & Prevention (a subsidiary of Johnson & Johnson) for the prevention of HIV-1 infection. The vaccine consists of two active components: a recombinant HIV-1 envelope glycoprotein gp140 of Clade C and a recombinant Mosaic gp140 engineered to represent multiple HIV-1 variants, both produced in the PER.C6 cell line and adjuvanted with aluminum phosphate. It was evaluated in combination with the viral vector vaccine Ad26.Mos4.HIV as a heterologous prime-boost regimen in the Phase 3 Mosaico efficacy trial (NCT03964415). In January 2023, the trial was discontinued after an independent data safety monitoring board determined that the regimen lacked efficacy in preventing HIV-1 infection compared to placebo, though no safety concerns were identified.
- Other names
- Adjuvanted Clade C and Mosaic gp140 HIV Bivalent Vaccine, RecombinantClade C and Mosaic gp140 HIV Bivalent Vaccine, Recombinant
02
Targets
BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on Clade C gp140 HIV bivalent vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clade C gp140 HIV bivalent vaccine.